Genetic mosaicism in basal cell carcinoma
2005 (English)In: Experimental dermatology, ISSN 0906-6705, E-ISSN 1600-0625, Vol. 14, no 8, 593-600 p.Article in journal (Refereed) Published
Human basal cell cancer (BCC) shows unique growth characteristics, including a virtual inability to metastasize, absence of a precursor stage and lack of tumour progression. The clonal nature of BCC has long been a subject for debate because of the tumour growth pattern. Despite a morphologically multifocal appearance, genetic analysis and three-dimensional reconstructions of tumours have favoured a unicellular origin. We have utilized the X-chromosome inactivation assay in order to examine clonality in 13 cases of BCC. Four parts of each individual tumour plus isolated samples of stroma were analysed following laser-assisted microdissection. In 12/13 tumours, the epithelial component of the tumour showed a monoclonal pattern suggesting a unicellular origin. Surprisingly, one tumour showed evidence of being composed of at least two non-related monoclonal clones. This finding was supported by the analysis of the ptch and p53 gene. Clonality analysis of tumour stroma showed both mono- and polyclonal patterns. A prerequisite for this assay is that the extent of skewing is determined and compensated for in each case. Owing to the mosaic pattern of normal human epidermis, accurate coefficients are difficult to obtain; we, therefore, performed all analyses both with and without considering skewing. This study concludes that BCC are monoclonal neoplastic growths of epithelial cells, embedded in a connective tissue stroma at least in part of polyclonal origin. The study results show that what appears to be one tumour may occasionally constitute two or more independent tumours intermingled or adjacent to each other, possibly reflecting a local predisposition to malignant transformation.
Place, publisher, year, edition, pages
2005. Vol. 14, no 8, 593-600 p.
Carcinoma; Basal Cell/*genetics/metabolism, Cell Transformation; Neoplastic, Chromosome Aberrations, Chromosomes; Human; X, DNA/metabolism, Disease Progression, Dosage Compensation; Genetic, Epidermis/metabolism, Epithelium/metabolism, Female, Heterozygote, Humans, Lasers, Loss of Heterozygosity, Mosaicism, Neoplasms; Glandular and Epithelial/*genetics/metabolism, Receptors; Androgen/*genetics, Research Support; Non-U.S. Gov't, Tumor Suppressor Protein p53/metabolism
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-93046DOI: 10.1111/j.0906-6705.2005.00333.xPubMedID: 16026581OAI: oai:DiVA.org:uu-93046DiVA: diva2:166404